| 2024-11-07 | +2.71 % |
|
| 2024-11-05 | -0.01 % |
|
| 2024-11-04 | -1.56 % |
|
| 2024-10-30 | -6.28 % |
|
| 2024-10-29 | +0.89 % |
|
| 2024-10-23 | -0.65 % |
|
| 2024-10-22 | +0.33 % |
|
| 2024-10-09 | +0.66 % |
|
| 2024-10-02 | +0.75 % |
|
| 2024-10-01 | -0.16 % |
|
| 2024-09-30 | +0.93 % |
|
| 2024-09-27 | -3.47 % |
|
| 2024-09-20 | +0.7 % |
|
| 2024-09-19 | +1.11 % |
|
| 2024-09-12 | +1.53 % |
|
| 2024-09-10 | -0.77 % |
|
| 2024-09-09 | +0.62 % |
|
| 2024-09-06 | -1.1 % |
|
| 2024-09-04 | -1.07 % |
|
| 2024-08-15 | -0.01 % |
|
| 2024-08-14 | +2.6 % |
|
| 2024-08-13 | +2.68 % |
|
| 2024-08-12 | -0.82 % |
|
| 2024-08-09 | +5.49 % |
|
| 2024-08-07 | -2.65 % |
|
| 2024-08-05 | -3.63 % |
|
| 2024-08-01 | +3.5 % |
|
| 2024-07-25 | -4.5 % |
|
| 2024-07-24 | -2.1 % |
|
| 2024-07-23 | +1.42 % |
|
| 2024-07-22 | +0.99 % |
|
| 2024-07-18 | -6.26 % |
|
| 2024-07-15 | +0.22 % |
|
| 2024-07-11 | -0.6 % |
|
| 2024-07-09 | +1.58 % |
|
| 2024-07-05 | +1.83 % |
- The article discusses the upward movement (1.83%) of Eli Lilly & Co (LLY) stock and emphasizes that the Vanguard US Total Market Shares Index ETF (ASX: VTS) has been a beneficial investment in the last five years due to its low management fees (0.03%), positive financial characteristics of businesses within the US share market (ROE of 24%, earnings growth rate of 15.7%), and potential for shareholder returns. The performance of US stocks and ETFs is largely influenced by tech giants like Nvidia, Microsoft, Apple, and Amazon, among others, which might impact diversification.
- Eli Lilly & Co (LLY) stock was up by 1.83% last night; the stock's increase is attributed to promising data on its tirzepatide injection (Mounjaro), showing a significant reduction in sleep apnea events compared to a placebo during trials, which positively affected investor sentiment and contributed to the stock's uptrend.
|
| 2024-07-02 | -0.84 % |
|
| 2024-07-01 | +0.99 % |
|
| 2024-06-27 | +0.86 % |
|
| 2024-06-26 | -0.37 % |
|
| 2024-06-25 | +1.63 % |
|
| 2024-06-24 | +0.7 % |
- The article discusses Meta Platforms Inc. (NASDAQ:META) COO Javier Olivan selling a portion of his company stock and mentions various insider transactions in different tech companies like Meta Platforms, Eli Lilly & Co (LLY), NVIDIA Corporation, and Alphabet Inc. One possible reason for Eli Lilly & Co (LLY) stock going up could be the positive financial health and market position of the company, as outlined by InvestingPro data, indicating strong balance sheet, impressive gross profit margins, significant market capitalization, and robust revenue growth.
- Eli Lilly & Co (LLY) stock increased by 0.7% last night following news of a potential boost due to supply issues at competitor Novo Nordisk A/S (NVO), especially related to Eli Lilly's weight loss drug Zepbound, as suggested by a Reddit user.
- Eli Lilly & Co (LLY) stock went up by 0.7% on Monday due to a positive clinical trial showing their weight-loss drug Zepbound reducing the severity of sleep apnea among obese patients without the need for a sleep apnea mask, contrasting with ResMed (RMD) shares plunging 11.5%.
|
| 2024-06-21 | -0.24 % |
|
| 2024-06-18 | +0.73 % |
|
| 2024-06-17 | +0.75 % |
|
| 2024-06-13 | +1.85 % |
- The article discusses Mark A. Stevens, a director of Nvidia Corp (NVDA), selling a substantial amount of company stock, potential reasons for this sale, and various recent developments in the tech and finance sectors. Although the article does not directly explain the specific reason for Eli Lilly & Co (LLY) stock going up, it can be inferred that positive market sentiments, such as significant gains in technology stocks and positive growth outlook for certain companies, may have contributed to the increase in LLY stock price.
- The article discusses why Eli Lilly & Co (LLY) stock went up by 1.85% following a positive advisory committee meeting for their Alzheimer's drug, donanemab, with unanimous agreement on its efficacy outweighing safety risks, potentially impacting Eisai Co stock negatively despite Bernstein SocGen maintaining a positive stance on Eisai in anticipation of FDA approval for donanemab.
|
| 2024-06-11 | +0.09 % |
- The article mentions that Eli Lilly & Co (LLY) stock went up by 0.09% last night, and the stock may have increased due to positive news regarding their experimental Alzheimer's drug, Donanemab, which received backing from the FDA advisers as a potential effective treatment for Alzheimer's disease in patients with mild cognitive impairment and mild dementia.
- The recent article discusses a substantial sale of Eli Lilly & Co (LLY) shares by Lilly Endowment Inc, a major shareholder, which raised nearly $65 million, and despite this sale, Eli Lilly & Co's stock went up by 0.09%. The stock may have increased due to strong performance metrics, a potential upcoming FDA approval for its Alzheimer's drug, donanemab, positive outlook from analysts, strategic efforts in oncology, and the company's poised position in the expanding weight-loss drug market.
|
| 2024-06-10 | +1.77 % |
|
| 2024-06-07 | +1.52 % |
|
| 2024-06-05 | -0.1 % |
|
| 2024-05-24 | -0.13 % |
- The article discusses the recent trend of high-priced tech companies considering stock splits, with companies like Nvidia Corp. leading the way with a 10-for-1 split, which could potentially make stocks more accessible to retail investors, though the actual value of investors' stake remains the same; as tech companies like Nvidia, Microsoft, Meta Platforms, Broadcom, Super Micro Computer, ServiceNow, Netflix, and Booking Holdings are mentioned as potential candidates for stock splits due to high share prices. Eli Lilly & Co.'s stock might have gone down due to general market movements or specific company-related news not discussed in the article.
- In a recent transaction, major shareholder Lilly Endowment Inc sold a significant number of shares in Eli Lilly & Co (NYSE:LLY), causing its stock to go down by -0.13% last night; the stock decrease could be attributed to market fluctuations and perceived implications on the company's financial health and future prospects due to the sale of shares by a major shareholder.
|
| 2024-05-21 | +2.55 % |
|
| 2024-05-20 | +1.71 % |
|
